Amivantamab Plus Lazertinib Improved PFS for EGFR-Mutated Ad

MARIPOSA demonstrated the combination reduced risk of progression or death by 30% compared with osimertinib. MARIPOSA-2 found amivantamab plus chemotherapy and amivantamab plus chemotherapy and lazertinib also improved progression-free survival (PFS) over chemotherapy after progression on osimertinib.

Related Keywords

Milan , Lombardia , Italy , Madrid , Spain , Massachusetts , United States , Seoul , Soult Ukpyolsi , South Korea , Republic Of Korea , Antonio Passaro , Byoung Chul Cho , Zofia Piotrowska , Yonsei University College Of Medicine , Harvard Medical School , European Institute Of Oncology , Yonsei Cancer Center , Division Of Thoracic Oncology , Harvard Medical School Zofia Piotrowska , Yonsei University College , Thoracic Oncology , European Institute , Massachusetts General Hospital , Esmo Congress , Amivantamab , Lazertinib , Osimertinib , Nsclc ,